Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. - Wikidata - wikimedia - TriplyDB

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.

http://www.wikidata.org/entity/Q41137675

about

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Impact of new treatment options for hepatitis C virus infection in liver transplantation Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients Anti-hepatitis C virus drugs and kidney Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Hepatitis C Virus and Liver Transplantation.Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Use of Hepatitis C-Positive Donor Livers in Liver Transplantation.Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Is it time to rethink combined liver-kidney transplant in hepatitis C patients with advanced fibrosis?Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.The future of liver transplantation for viral hepatitis.Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation.Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin."Targeting" hepatitis C after liver transplantation.Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation.Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center.

P2860

Q26740319-7F2A5635-71E2-4C2E-8381-82F4EB9B5E10 Q26782017-E3AF250C-7AD2-48F1-93F7-CC9463EB059A Q26795595-7A54402D-FECD-4D8C-898E-EE5C99C370C1 Q28070279-00D43F9D-17F4-4D59-BAEF-4D27EC92BEB2 Q28076883-5EEF73AF-6D0F-4C9A-B13A-7D7BC472B785 Q33717116-A8AA2E90-FB3D-40B6-828A-1DB6CB63AA3F Q36077546-8FECFAAE-E477-47FE-A523-7965BF2F9379 Q36165389-B59973EC-5FBE-4DE4-9009-7FD4A67EDE94 Q36292616-974774C8-D54A-4741-BF2C-4B787A0DF341 Q36875036-A9B0B5D6-6175-453C-B18A-E9E4ED14348F Q37349067-8B028B8D-DB37-4C1C-9478-ECE90C4D0377 Q37552703-4BA4A9BE-CE07-4C6B-97D5-8BD3A9AB64DD Q37651918-AE366D8B-149D-4468-938C-9D9769DD4AF9 Q38384095-B4C85D0A-95C1-491C-9BBE-6DED68723745 Q38769679-597939CC-FCB6-4CB6-A2FE-EDC99B29FE20 Q38774864-25BDA985-7EE9-4F5E-91AC-C82356CFDA91 Q38845669-C9E8D04C-784E-41B3-B412-D873B9658F4E Q38859081-44B0E030-2DA8-4A1E-A750-E7FD698FED29 Q38872799-1712B69A-45A9-4BAB-8D44-82A1A5FD00F5 Q38954096-FBD2BC0A-437E-4D4E-9C60-447E13797E8C Q39108672-442C27C6-941B-4436-9AFF-4F887A9DDD72 Q39139767-09AA7DF7-A4AD-476B-B9D7-3C35FAAB2BF5 Q39609174-0A92C986-27A4-4846-9A7E-6EFB9AD1414B Q39885523-F22EDCE4-BB46-4D61-9EE7-1C9F3082A7EF Q39968319-4B386721-9448-4002-A871-B14F15E8A7F5 Q40141719-F849C473-F4EC-4FA3-8143-0F053ED1B8A7 Q40278284-05AC9154-5798-494A-8674-5BD016F97708 Q40291443-1322287D-57E4-4D92-88A1-55E7A54FF249 Q40352380-D8FB7BC1-BC80-4174-B25B-2565DFA5463A Q40373543-8753FD95-0F2F-4927-9A80-1AE8BE3D706A Q40400190-F0710DF8-DCF5-48A7-B172-1D81CD601BDD Q40473486-E074BB36-663F-4C57-9B6C-DC9ABE5E7842 Q40584810-B6CD2B84-0450-4309-B262-6B45A4B38C56 Q40635393-A5B0E8B9-8426-473F-8710-B2CF247806BC Q40705980-3A6F7DB9-D020-4574-85A9-7083D009BD0F Q42148776-68340D22-F382-4988-B5A3-2B087C6A7168 Q42984704-07A4771D-4CBB-484C-9CE5-D56FD720F76F Q51000411-1B776E65-12C7-4AE1-ABAC-B0D9CA040940 Q55353924-F77FC1E9-025A-4437-B608-A7FA3FF47558

P2860

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.

http://www.wikidata.org/entity/Q41137675

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sofosbuvir and simeprevir for ...... n liver transplant recipients.

@en

type

label

Sofosbuvir and simeprevir for ...... n liver transplant recipients.

@en

prefLabel

Sofosbuvir and simeprevir for ...... n liver transplant recipients.

@en

P1433

Q41137675-0979F1E3-88C9-4F76-9B84-9A740A000030

P1476

Q41137675-47D65F05-C75C-449C-B11E-BB1F7F3B25A9

P2093

Q41137675-2CF2FCF8-CF74-4966-B6E6-4CFFD99EAAFA

Q41137675-3479DEA7-5859-4DF4-86FC-938687E147BB

Q41137675-54368DE6-299A-4BC1-BF5E-D1CC3D9EC849

Q41137675-7DAB8EBC-726B-4860-B669-C795FB5B9023

Q41137675-9A8084C4-917C-4B53-9B91-3BE94EEFB928

Q41137675-9AFB1AD3-5045-4C9E-8802-2C1EC26A63B6

Q41137675-B8770918-9BBE-48FD-A3CB-0F5F938ADE07

P2860

Q41137675-006A17F2-EAE8-4233-B123-603909D358EC

Q41137675-04CABCE2-9355-4349-920C-194BD786D325

Q41137675-20D93025-6317-4029-A694-86EED216F5AE

Q41137675-22E650BC-C6BF-4897-BE2E-87FBFC0ABB0F

Q41137675-317667E7-F639-426F-A8E3-773E44C9C315

Q41137675-364C0E09-CFF2-4B7A-BC8E-793C1598940B

Q41137675-37ACB1CF-F42D-4A32-8B81-74D8A35DB89E

Q41137675-3C8F13FE-2740-40DB-B839-183AB456784D

Q41137675-59133BB7-112F-4948-9F1A-C9EC59AD72F0

Q41137675-5A30E536-A6D1-47B6-9F03-DD2FD9B86028

P304

Q41137675-444361FE-0D55-4F93-922E-065A1135293C

P31

Q41137675-FE512FA5-F48F-4816-A0F5-0BED7CB3406A

P356

Q41137675-C12665C3-995C-4E55-A527-A310CBA49740

P433

Q41137675-3BA3D878-6A33-4A2E-BFDF-5FF61492E32C

P478

Q41137675-0342BA14-98BC-405A-960F-CA36AF16F501

P577

Q41137675-AC892C50-37C3-43E0-B8C4-2914DE183DF1

P5875

Q41137675-8AEA2177-41E3-4046-95E5-F61FA92F118B

P698

Q41137675-04F90376-A955-4058-A6FB-202804AB7F08

P921

Q41137675-756FA65D-6534-4621-9F7C-2030AB868385

P932

Q41137675-2FB4DD77-B829-4563-9992-BF77E4E03338

P356

P1433

Liver Transplantation

P1476

Sofosbuvir and simeprevir for ...... in liver transplant recipients

@en

P2093

Adam Peyton

http://www.w3.org/2001/XMLSchema#string

Andres F Carrion

http://www.w3.org/2001/XMLSchema#string

Christopher O'Brien

http://www.w3.org/2001/XMLSchema#string

Danny Avalos

http://www.w3.org/2001/XMLSchema#string

Julio A Gutierrez

http://www.w3.org/2001/XMLSchema#string

Kalyan Ram Bhamidimarri

http://www.w3.org/2001/XMLSchema#string

Paul Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Diagnosis, management, and treatment of hepatitis C: an update

Sofosbuvir for previously untreated chronic hepatitis C infection

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Management of hepatitis C infection after liver transplantation.

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.

The natural history of recurrent hepatitis C and what influences this.

Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.

Recurrent HCV after liver transplantation-mechanisms, assessment and therapy.

An interferon-free antiviral regimen for HCV after liver transplantation.

P304

823-830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/LT.24126

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274264580

http://www.w3.org/2001/XMLSchema#string

P698

25825070

http://www.w3.org/2001/XMLSchema#string

P921

P932

6658191

http://www.w3.org/2001/XMLSchema#string